文献速递前列腺癌

量化前列腺癌Gleason 4模式预测肿瘤学结局

Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.
PubMed 文献 · BJU Int · 2025-08-07

本研究回顾性分析446例接受MRI引导穿刺和根治性前列腺切除术的Gleason分级分组2-4级前列腺癌患者,比较穿刺活检Gleason分级分组、Gleason 4模式百分比、毫米数及基于MRI病灶体积的Gleason 4模式体积对转移复发的预测价值。中位随访6.9年,46例发生转移。结果显示基于MRI和靶向穿刺的Gleason 4模式体积预测任何转移的C指数达0.80,优于CAPRA评分(0.72)和穿刺Gleason分级分组(0.70)。

要点

  • 术前基于MRI和靶向穿刺估算Gleason 4模式体积可预测转移复发。
  • Gleason 4模式体积C指数0.80,优于CAPRA评分0.72和穿刺GG 0.70。
  • 需进一步研究Gleason 4模式量化方法以纳入治疗决策。

核心结论

  • 对于活检和/或根治标本无Gleason 5模式的GG 2-4前列腺癌患者,术前基于MRI和靶向穿刺估算的Gleason 4模式体积在预测任何及远处转移复发方面优于Gleason评分分类和标准风险评分。

研究设计与样本

  • 回顾性研究纳入2009至2018年接受MRI引导穿刺和根治性前列腺切除术的患者,共446例,中位随访6.9年(无事件患者)。

主要发现

  • 46例患者发生任何转移。
  • 基于穿刺结果预测任何转移复发时,CAPRA评分C指数0.72,穿刺GG C指数0.70。
  • Gleason 4模式百分比C指数0.74,毫米数C指数0.77,体积C指数0.80。

临床怎么用

  • 对于GG 2-4且含Gleason 4模式的前列腺癌患者,可考虑术前使用MRI和靶向穿刺量化Gleason 4模式体积以辅助预测转移风险。

局限性

  • 需进一步研究量化Gleason 4模式的最佳方法,之后才能纳入治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if quantifying Gleason pattern 4 (GP4) is superior to Grade Group (GG) in predicting any and distant metastatic recurrence after radical prostatectomy (RP) for prostate cancer, and compare various GP4 quantification methods for predicting metastatic recurrence using preoperative targeted biopsy and magnetic resonance imaging (MRI) data. PATIENTS AND METHODS: We conducted a retrospective study of patients who underwent MRI-guided biopsies and RP from 2009 to 2018. Patients with GG 2-4 without GP5 disease on biopsy and/or RP specimen were included. The predictors compared were biopsy GG, percentage of GP4 in biopsy cores, millimetres of GP4 in biopsy cores, and volume of GP4 based on MRI lesion volume. These methods were also compared to the Cancer of the Prostate Risk Assessment (CAPRA), International Staging Collaboration for Cancer of the Prostate (STAR-CAP), European Association of Urology (EAU), and National Comprehensive Cancer Network (NCCN) risk classifications. The C-index for each model was calculated to evaluate discrimination performance. RESULTS: A total of 446 patients were analysed, with a median follow-up of 6.9 years for patients without an event; 46 patients developed any metastasis. For any metastatic recurrence based on biopsy findings, the CAPRA score (C-Index = 0.72) showed the highest discrimination among risk scores, surpassing biopsy GG (C-Index = 0.70), but was outperformed by percentage GP4 (C-Index = 0.74), millimetres GP4 (C-Index = 0.77), and volume of GP4 (C-Index = 0.80). CONCLUSION: For patients with GG 2-4 prostate cancer containing GP4, preoperative GP4 volume estimation using MRI and targeted biopsy outperforms Gleason scoring classification and standard risk scores in predicting any and distant metastatic recurrence. Further research is warranted on the best methods to quantify GP4 before incorporation in treatment decision-making.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Olivier J, Vertosick E, Delobel L, et al. Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome. BJU Int. 2025. PMID: 40774801. doi:10.1111/bju.16884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。